Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival Trends of People With Spina Bifida From 1950-2020.

JAMA pediatrics·2026
Same author

Establishing a clinician-prioritized pediatric urology clinical research agenda in the United States.

Journal of pediatric urology·2026
Same author

Microglia mediate sex-dependent memory deficits in pelvic pain.

American journal of physiology. Regulatory, integrative and comparative physiology·2026
Same author

Gut Microbiome-Driven Microglial Activation Links Dysbiosis to Pain in Interstitial Cystitis/Bladder Pain Syndrome.

Research square·2026
Same author

Epigenetic Regulation of Immune Dysfunction in Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

The Prostate·2026
Same author

Reply by Authors.

Urology practice·2026

Related Experiment Video

Updated: Jan 6, 2026

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
06:46

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis

Published on: January 16, 2013

16.4K

TRPV1 in experimental autoimmune prostatitis.

Kenny Roman1, Christel Hall1, Anthony J Schaeffer1

  • 1Departments of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

The Prostate
|October 2, 2019
PubMed
Summary

Transient Receptor Potential Vanilloid 1 (TRPV1) channel is crucial for chronic pelvic pain in a mouse model. Blocking TRPV1 offers a potential therapeutic strategy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

Keywords:
CPPSinflammationmast cellspelvic painvanilloid 1

More Related Videos

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

8.8K
Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation
09:49

Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation

Published on: August 13, 2015

9.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
06:46

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis

Published on: January 16, 2013

16.4K
Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
06:04

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice

Published on: September 2, 2020

8.8K
Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation
09:49

Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation

Published on: August 13, 2015

9.7K

Area of Science:

  • Neuroscience
  • Urology
  • Pain Research

Background:

  • Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) causes persistent pelvic pain in men.
  • The Transient Receptor Potential Vanilloid 1 (TRPV1) channel is implicated in various chronic pain pathways.
  • TRPV1's role in CP/CPPS-associated chronic pelvic pain has not been previously established.

Purpose of the Study:

  • To investigate the involvement of the TRPV1 channel in a murine model of CP/CPPS (experimental autoimmune prostatitis - EAP).
  • To evaluate the therapeutic potential of blocking TRPV1 in managing chronic pelvic pain.

Main Methods:

  • Utilized male C57BL/6J (B6) and TRPV1 knockout (TRPV1 KO) mice in the EAP model.
  • Assessed pelvic allodynia, prostate inflammation, mast cell activity, and p-ERK1/2 levels in DRG and spinal cord.
  • Administered intraurethral TRPV1 antagonist to B6 mice with EAP to evaluate pain reduction.

Main Results:

  • B6 mice with EAP developed pelvic tactile allodynia, unlike TRPV1 KO mice.
  • TRPV1 KO mice showed reduced mast cell activation in the prostate despite inflammation.
  • TRPV1 antagonism via intraurethral infusion significantly reduced pelvic tactile allodynia in B6 mice with EAP.

Conclusions:

  • The TRPV1 channel is critical for developing persistent pelvic tactile allodynia in a murine CP/CPPS model.
  • Blocking TRPV1 in the prostate presents a promising therapeutic strategy for alleviating chronic pelvic pain in CP/CPPS.